These findings suggest that immunomodulatory therapy, including IFN-β, may not only exert a direct effect on reducing disease activity and progression, as indicated by improved EDSS scores but also enhance the antioxidant defense system, which could mitigate oxidative stress in RRMS patients. The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.